Innocan files amendment for U.S. public offering

Executive Summary

• Innocan Pharma Corp. has publicly filed an amendment to its Form F-1 registration statement with the SEC for a proposed U.S. public offering of units.
• The offering involves the issuance of units, each consisting of one common share and one common share purchase warrant.
• The company has applied for listing on the NYSE American under the symbols INNP and INNPW, with ThinkEquity LLC acting as the sole book-running manager.

Key Details

• Filing Details: Amendment to Form F-1 registration statement filed with the U.S. Securities and Exchange Commission (SEC).
• Original Filing Date: July 23, 2025.
• Offering Structure: Units comprising one common share and one common share purchase warrant per unit.
• Warrant Terms: Each warrant entitles the holder to purchase one common share at an exercise price and term determined in the context of the market.
• Listing Application: Applied to list common shares and warrants on the NYSE American exchange.
• Ticker Symbols: INNP (common shares) and INNPW (warrants).
• Underwriter: ThinkEquity LLC is acting as the sole book-running manager.
• Distribution Method: Offering made only by means of a prospectus; preliminary prospectus available from ThinkEquity upon availability.
• Regulatory Status: Registration statement filed but not yet effective; no sales or offers to buy may be accepted prior to effectiveness.

Notable Quotes

• No direct quotes from management were included in the provided text.